EGFR and head and neck squamous cell carcinoma: Platinum-based systemic chemotherapy in combination with the monoclonal antibody cetuximab, targeting the epidermal growth factor receptor (EGFR) has been the standard of care for recurrent or metastatic (r/m) SCCHN for over a decade (1, 2).